Faculty Information |
|
Language | English |
The announcement title | "Hot topics in urogenital tract infections" Antibiotic resistance as a major problem in the management of urogenital infection |
Academic Society name | the 30th International Congress of Chemotherapy and Infection 2017 (ICC 2017) |
Conference Type | International Society |
Invitation | Invitation |
Announcement form | Oral presentation |
Presentation Type | Symposium/Workshop/Panel Discussion |
Lecture Type | Symposium/Workshop/Panel Discussion |
Publisher and common publisher | Yamamoto Shingo |
Date | 2017/11/27 |
Venue (city and name of the country) |
Taipei |
Society abstract | International Journal of Antimicrobial Agents 50(Suppl.2),S25-6 2017 |
Description | Antibiotic resistance has become a serious problem during management of patients with urinary tract infections (UTIs). Enterobacteriaceae are a family of gram-negative bacteria known to cause community- and hospital acquired UTIs. These organisms have an ability to acquire genes related to multiple antibiotic resistance mechanisms, including extended-spectrum-lactamases (ESBLs), AmpC β-lactamase, and carbapenemases. In addition, fluoroquinolone resistant bacteria are associated with certain ESBL genotypes.Developments of novel combinations of β-lactam/β-lactamase inhibitors, such as ceftolozane/tazobactam and ceftazidime/avi- bactam, have been helpful in this era of shortage of novel antibiotic agents for overcoming multidrug resistant Enterobacteriaceae. Both of those combinations have been shown to have activities against multidrug resistant microorganisms in vitro; notably ceftazidime/avibactam, which was reported to consistently dem- onstrate activities against Klebsiella pneumoniae carbapenemase- producing organisms.However, in consideration of possible adverse effects, such novel antibiotics should not be used as the first choice, but rather reserved for cases in which no alternative drug is available. Also, use of fluoroquinolones and third generation cephalosporins for empiric treatment of UTIs should be restricted due to increasing rates of resistance. For example, most strains of E. coli and Klebsiella producing ESBL are susceptible to certain oral drugs, such as fosfomycin, as well as intravenous injection drugs, including amikacin, piperacillin/tazobactam, and carbapenem, thus the attending physician should be familiar with the antibiogram in their area and wisely prescribe such drugs for empiric or definitive therapy. ... |